Literature DB >> 24272362

The role of complement in tumor growth.

Ruben Pio1, Leticia Corrales, John D Lambris.   

Abstract

Complement is a central part of the immune system that has developed as a first defense against non-self cells. Neoplastic transformation is accompanied by an increased capacity of the malignant cells to activate complement. In fact, clinical data demonstrate complement activation in cancer patients. On the basis of the use of protective mechanisms by malignant cells, complement activation has traditionally been considered part of the body's immunosurveillance against cancer. Inhibitory mechanisms of complement activation allow cancer cells to escape from complement-mediated elimination and hamper the clinical efficacy of monoclonal antibody-based cancer immunotherapies. To overcome this limitation, many strategies have been developed with the goal of improving complement-mediated effector mechanisms. However, significant work in recent years has identified new and surprising roles for complement activation within the tumor microenvironment. Recent reports suggest that complement elements can promote tumor growth in the context of chronic inflammation. This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24272362      PMCID: PMC4379038          DOI: 10.1007/978-1-4614-5915-6_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  257 in total

Review 1.  Effects of the membrane attack complex of complement on nucleated cells.

Authors:  B P Morgan
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells.

Authors:  M T Holmberg; A M Blom; S Meri
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

3.  Protein S in cancer patients with non-metastatic solid tumours.

Authors:  S Battistelli; A Vittoria; R Cappelli; M Stefanoni; F Roviello
Journal:  Eur J Surg Oncol       Date:  2005-09       Impact factor: 4.424

4.  Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Authors:  Pina M Cardarelli; Maire Quinn; Dana Buckman; Yu Fang; David Colcher; David J King; Christopher Bebbington; Geoffrey Yarranton
Journal:  Cancer Immunol Immunother       Date:  2001-12-18       Impact factor: 6.968

Review 5.  Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism.

Authors:  Kristine Glunde; Natalie J Serkova
Journal:  Pharmacogenomics       Date:  2006-10       Impact factor: 2.533

6.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

Authors:  J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 7.  Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

Authors:  Z Fishelson; N Donin; S Zell; S Schultz; M Kirschfink
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

8.  A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.

Authors:  H Juhl; M Sievers; K Baltzer; F Helmig; H Wolf; W Brenner; H Kalthoff
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

9.  Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55.

Authors:  Rachel J M Abbott; Ian Spendlove; Pietro Roversi; Hannah Fitzgibbon; Vroni Knott; Peter Teriete; James M McDonnell; Penny A Handford; Susan M Lea
Journal:  J Biol Chem       Date:  2007-04-20       Impact factor: 5.157

10.  Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.

Authors:  S Bellone; D Roque; E Cocco; S Gasparrini; I Bortolomai; N Buza; M Abu-Khalaf; D-A Silasi; E Ratner; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

View more
  83 in total

1.  Tag SNPs of CFI contributed to the susceptibility for non-small cell lung cancer in Chinese population.

Authors:  Yingwen Liu; Yanghui Bi; Jia Lin; Lei Cao; Bing He; Zhi Zhang; Yongping Cui; Xuemei Zhang
Journal:  Tumour Biol       Date:  2014-11-15

2.  Complement-dependent modulation of antitumor immunity following radiation therapy.

Authors:  Michelle Elvington; Melissa Scheiber; Xiaofeng Yang; Katherine Lyons; Dustin Jacqmin; Casey Wadsworth; David Marshall; Kenneth Vanek; Stephen Tomlinson
Journal:  Cell Rep       Date:  2014-07-24       Impact factor: 9.423

Review 3.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

4.  Mutation Drivers of Immunological Responses to Cancer.

Authors:  Eduard Porta-Pardo; Adam Godzik
Journal:  Cancer Immunol Res       Date:  2016-07-11       Impact factor: 11.151

5.  Evaluation of Serum Glycoprotein Biomarker Candidates for Detection of Esophageal Adenocarcinoma and Surveillance of Barrett's Esophagus.

Authors:  Alok K Shah; Gunter Hartel; Ian Brown; Clay Winterford; Renhua Na; Kim-Anh Lê Cao; Bradley A Spicer; Michelle A Dunstone; Wayne A Phillips; Reginald V Lord; Andrew P Barbour; David I Watson; Virendra Joshi; David C Whiteman; Michelle M Hill
Journal:  Mol Cell Proteomics       Date:  2018-08-10       Impact factor: 5.911

6.  Revelation of Proteomic Indicators for Colorectal Cancer in Initial Stages of Development.

Authors:  Arthur T Kopylov; Alexander A Stepanov; Kristina A Malsagova; Deepesh Soni; Nikolay E Kushlinsky; Dmitry V Enikeev; Natalia V Potoldykova; Andrey V Lisitsa; Anna L Kaysheva
Journal:  Molecules       Date:  2020-01-31       Impact factor: 4.411

7.  Complementing the tumor-specific immunity in tumor radiotherapy.

Authors:  Linjie Zhao; Shengtao Zhou
Journal:  Ann Transl Med       Date:  2016-08

8.  Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.

Authors:  Weiyi Peng; Jodi A McKenzie; Patrick Hwu
Journal:  Cancer Discov       Date:  2016-09       Impact factor: 39.397

9.  Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Authors:  Laura M Rogers; Sarah L Mott; Brian J Smith; Brian K Link; Deniz Sahin; George J Weiner
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

10.  Identification of complement inhibitory activities of two chemotherapeutic agents using a high-throughput cell imaging-based screening assay.

Authors:  Lingjun Zhang; Yuriy Fedorov; Drew Adams; Feng Lin
Journal:  Mol Immunol       Date:  2018-06-15       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.